PMI Form 3/A: CEO Schnegelsberg Discloses 2.38M Options; Exercise Price Adjusted
Rhea-AI Filing Summary
Picard Medical, Inc. reporting person Patrick Schnegelsberg, identified as both a director and the company's Chief Executive Officer, filed an amended Form 3 to report equity derivative holdings. The amendment corrects the conversion/exercise price to reflect a combined 1 for 2.1524 forward stock split adjustment (a 1 for 2.2 forward split followed by a 1.0221 for 1 reverse split). The filing shows 2,378,124 employee stock options underlying common stock with an exercise price of $0.71 (as adjusted). The options were granted June 28, 2024, with a vesting commencement date of July 5, 2023: one quarter cliff vested on the first anniversary and the remainder vests monthly over the subsequent 36 months, subject to continued service. The Form 3/A is signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Reporting person holds 2,378,124 employee stock options, providing alignment of executive incentives with shareholder value.
- Vesting schedule disclosed: 25% cliff at first anniversary with the remainder vesting monthly over 36 months, tying compensation to continued service.
- Amendment corrects exercise price for stock-split adjustments, improving public transparency under Section 16 reporting requirements.
Negative
- None.
Insights
TL;DR: Routine Section 16 amendment correcting option exercise price after stock-split adjustments; reporting officer holds a multi-year vested option award.
The amended Form 3 clarifies the adjusted exercise price following corporate stock-split actions and discloses a sizable option grant of 2,378,124 shares awarded on June 28, 2024. The vesting schedule—25% at the first anniversary, then monthly over 36 months—aligns with common executive equity incentive practices and ties long-term compensation to continued service. This filing is procedural in nature and does not report any immediate sale or purchase of underlying shares; it updates the public record for Section 16 compliance.
TL;DR: Disclosure improves transparency on CEO compensation mechanics after corporate capitalization changes; no new transactions reported.
The Form 3/A addresses a technical correction to option pricing after a combined forward/reverse split and documents the CEO's option holdings and vesting terms. The filing reinforces standard governance practice by timely amending Section 16 reporting to reflect corporate actions that alter per-share metrics. There is no indication of accelerated vesting, transfers, or other atypical arrangements in this disclosure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Options (right to buy) | -- | -- | -- |
Footnotes (2)
- F1. On June 28, 2024, the reporting person was granted 2,378,124 options, with a vesting commencement date of July 5, 2023. One quarter of the options cliff vested upon the first anniversary of the vesting commencement date, and the remaining options have vested or will vest ratably in equal monthly installments over the 36 months following the first anniversary of the vesting commencement date, generally subject to the continued service of the reporting person through each applicable vesting date.
- F2. As adjusted to reflect the Company's 1 for 2.2 forward stock split of the Company's common stock and the Company's 1.0221 for 1 reverse stock split of the Company's common stock, resulting in an overall forward stock split of 1 for 2.1524.
AI-generated analysis. How Rhea-AI works. Not financial advice.